Matthew C Garrett, Rebecca Albano, Troy Carnwath, Lubayna Elahi, Catherine A Behrmann, Merissa Pemberton, Daniel Woo, Eric O'Brien, Brett VanCauwenbergh, John Perentesis, Sanjit Shah, Matthew Hagan, Ady Kendler, Chuntao Zhao, Aditi Paranjpe, Krishna Roskin, Harley Kornblum, David R Plas, Q Richard Lu
Low-grade and secondary high-grade gliomas frequently contain mutations in the IDH1 or IDH2 metabolic enzymes that are hypothesized to drive tumorigenesis by inhibiting many of the chromatin-regulating enzymes that regulate DNA structure. Histone deacetylase inhibitors are promising anti-cancer agents and have already been used in clinical trials. However, a clear understanding of their mechanism or gene targets is lacking. In this study, the authors genetically dissect patient-derived IDH1 mutant cultures to determine which HDAC enzymes drive growth in IDH1 mutant gliomas...
August 1, 2023: Scientific Reports